Amylyx Pharmaceuticals Announces Formal Intention to Remove Relyvrio from the Market

CAMBRIDGE, Mass.--(BUSINESS WIRE) April 04, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the“Company”) today announced the Company has started a process with the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials